Curing leukemia ?

Non-pharmaceutical medical innovations and public healthThe use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress,detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness,raising concerns about long-term safety,medication adherence and healthcare costs. Although treatment cessation may be feasible in few selected patients achieving deep molecular responses,a definitive cure remains elusive owing to the discovery that TKIs spare quiescent leukemic stem cells (LSC). Understanding mechanisms underlying LSC behavior in TKI-treated patients may provide important clues to develop an array of strategies that ensure the complete destruction of LSC reservoirs and thereby offer CML patients a definitive cure.Cette présentation a été donnée dans le cadre du Scientific BRIO Day 2 organisé annuellement par le SIRIC BRIO et qui a pour but de réunir tous les acteurs du SIRIC BRIO et plus largement de la cancérologie à Bordeaux.

Disciplines : Cancer
Mots-clés : cancer,oncologie,thérapie,recherche
Type de document : image en mouvement
Type de ressource : lecture
Niveau : doctorat,higher education
Auteurs ou éditeurs : François-Xavier MAHON,Université de Bordeaux - Service Audiovisuel et Multimédia,Université de Bordeaux - Service Audiovisuel et Multimédia,Université de Bordeaux - Service Audiovisuel et Multimédia